The Evaluation of Tau Deposition with [<sup>18</sup>F]PI-2620 by Using a Semiquantitative Method in Cognitively Normal Subjects and Patients with Mild Cognitive Impairment and Alzheimer’s Disease

<div>Fusion images between [<sup>18</sup>F]PI-2620 PET and T1-weighted MRI in a CN subject. (a) No uptake of [<sup>18</sup>F]PI-2620 in the bilateral striatum, thalamus, white matter, and whole cortical region. (b) Subtle off-target binding in the midbrain and cingulate gyrus.</div>

Molecular Imaging

fig3

Figure 3

Figure 3: The Evaluation of Tau Deposition with [<sup>18</sup>F]PI-2620 by Using a Semiquantitative Method in Cognitively Normal Subjects and Patients with Mild Cognitive Impairment and Alzheimer’s Disease 

Figure 3 | The Evaluation of Tau Deposition with [18F]PI-2620 by Using a Semiquantitative Method in Cognitively Normal Subjects and Patients with Mild Cognitive Impairment and Alzheimer’s Disease 